Q-omics provides the consensus-scored FAM86B2 profile across patient tissues and cancer cell-line models. FAM86B2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM86B2 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, FAM86B2 RNA expression shows 15,008 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, BRCA, and THYM as cancer lineages where FAM86B2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86B2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86B2 survival associations across molecular data types. FAM86B2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86B2 RNA expression–survival associations across cancer types. High FAM86B2 expression shows favorable associations in HNSC, PAAD, MESO, BRCA, BLCA and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM86B2 RNA expression.
This table summarizes FAM86B2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86B2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86B2 shows lower tumor expression in BRCA, KIRC and PRAD and higher tumor expression in COAD, CHOL and STAD. The BRCA box plot shows higher FAM86B2 RNA expression in normal versus tumor tissue (log2 FC = −0.307, t-test p < 0.001).
This table shows molecular features associated with FAM86B2 in patient tissues and cancer cell lines. In patient samples, FAM86B2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM86B2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
